ACR Congress Review 2019

References
Bergman M, Tanaka Y, Citera G, Bahlas S, Ali M, Meerwein S, Song Y, Strand V. Upadacitinib treatment and the routine assessment of
patient index data 3 (RAPID3) among patients with rheumatoid arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A551.
Bergman M, Tundia N, Camp H, Meerwein S, Schlacher C, Goldschmidt D, Song Y, Strand V. Effects of upadacitinib on patient-reported
outcomes after 24 weeks in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic or biologic
disease-modifying anti-rheumatic drugs: results from SELECT-NEXT and SELECT-BEYOND phase 3 studies. Arthritis Rheumatol. 2019;
71 (suppl 10):A1352.
Bessette L, Dougados M, Mysler E, Genovese M, Kinch C, Kwok K, Lukic T, Girard T, Landry P, van Vollenhoven R. Impact of tofacitinib
on the individual components of the ACR composite score in patients with rheumatoid arthritis: a post hoc analysis of phase 3 trials.
Arthritis Rheumatol. 2019; 71 (suppl 10):A1348.
Buch M, Wells A, Rubbert-Roth A, Jain M, Schlacher C, Camp H, Li Y, Song Y, Nash P. A comparative analysis of upadacitinib
monotherapy and upadacitinib combination therapy for the treatment of rheumatoid arthritis from two phase 3 trials. Arthritis Rheumatol.
2019; 71 (suppl 10):A511.
Burmester G, Van den Bosch F, Bessette L, Kivitz A, Li Y, Friedman A, Pangan A, Camp H, Kremer J. Long-term safety and efficacy of
upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDs: Results at 60 weeks. Arthritis Rheumatol.
2019; 71 (suppl 10):A538.
Charles-Schoeman C, Sornasse T, Sokolove J. Treatment with upadacitinib is associated with improvements in reverse cholesterol
transport in patients with rheumatoid arthritis: correlation with changes in inflammation and HDL levels. Arthritis Rheumatol. 2019; 71 (suppl
10):A510.
Choy E, McInnes I, Cush J, Aelion J, Zhang Y, Khan N, Liu J, Camp H, Meerwein S, Rigby W, Cohen A. MACE and VTE across multiple
upadacitinib studies in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program. Arthritis Rheumatol. 2019; 71
(suppl 10):A846.
Citera G, Jain R, Irazoque F, Guzman R, Madariaga H, Gruben D, Wang L, Stockert L, Hsu M, Santana K, Ebrahim A, Ponce de Leon D.
Tofacitinib in patients with rheumatoid arthritis and indicative of depression and/or anxiety: a post hoc analysis of phase 3 and phase 3b/4
clinical trials. Arthritis Rheumatol. 2019; 71 (suppl 10):A1444.
Coates L, Mease P, Gladman D, Van den Bosch F, Rychlewska-Hanczewska A, Tasset C, Meuleners L, Trivedi M, Gao J, Besuyen R,
Helliwell P. Long-term safety of filgotinib in patients with psoriatic arthritis, week 52 safety data from a phase 2 open-label extension study.
Arthritis Rheumatol. 2019; 71 (suppl 10):A1534.
Cohen S, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, Liu S, Stockert L, Menon S, Keystone E. Efficacy and safety of tofacitinib modifiedrelease
11 mg once daily + MTX in RA patients with an inadequate response to MTX: open-label phase results from a global phase 3b/4
MTX withdrawal study. Arthritis Rheumatol. 2019; 71 (suppl 10):A1412.
Cohen S, Tuckwell K, Kunder R, Katsumoto T, Zhao R, Berman A, Damjanov N, Fedkov D, Jeka S, Genovese M. Efficacy and safety of
fenebrutinib, a BTK inhibitor, compared to placebo in rheumatoid arthritis patients with active disease despite TNF inhibitor treatment:
Randomised, Double Blind, Phase 2 Study. Arthritis Rheumatol. 2019; 71 (suppl 10):A929.
Cohen S, van Vollenhoven R, Winthrop K, Zerbini C, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa J, Burmester G.
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program. Arthritis Rheumatol.
2019; 71 (suppl 10):A509.
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy J, Mozaffarian N, Landewé R, Bae S,
Keystone E, Nash P. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate:
FINCH1 primary outcome results. Arthritis Rheumatol. 2019; 71 (suppl 10):A506.
Croiteru A, Lidar M, Reitblat T, Zisman D, Balbir-Gurman A, Meshiach T, Almog R, Elkayam O. Real life retention of tofacitinib in patients
with rheumatoid arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A1400.
Danto S, Shojaee N, Singh R, Manukyan Z, Mancuso J, Peeva E, Vincent M, Beebe J. Efficacy and safety of the selective interleukin-1
receptor associated kinase 4 inhibitor, PF-06650833, in patients with active rheumatoid arthritis and inadequate response to methotrexate.
Arthritis Rheumatol. 2019; 71 (suppl 10):A2909.
Di Paolo J, Downie B, Meng A, Mollova N, Yu Y, Han P. Evaluation of potential mechanisms underlying the safety observations of filgotinib
in clinical studies in RA. Arthritis Rheumatol. 2019; 71 (suppl 10):A59.
Dougados M, van der Heijde D, Bingham C, Taylor P, Fallon L, Woolcott J, Brault Y, Wang L, Kessouri M. The effect of tofacitinib on
residual pain in patients with psoriatic arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A1502.
Fleischmann R, Bergman M, Tundia N, Song I, Suboticki J, Song Y, Strand V. Patient-reported outcomes of upadacitinib versus
*Chairman’s Pick